ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
BOSTON, Jan. 27, 2016 -- Topokine Therapeutics, the biotechnology company pioneering topical medications to contour the face and body, announced today that it has initiated a Phase 2 study of TAT4 Gel for reduction of nasolabial folds. Commonly known as laugh lines, nasolabial folds are a common sign of aging. They are typically treated with injectable dermal fillers.
TAT4 Gel is the second product in Topokine’s innovative pipeline of topical adipomodulatory medicines. Applied to the skin once daily, TAT4 acts pharmacologically to increase subcutaneous fat, thereby softening skin wrinkles and folds. As part of the randomized, placebo-controlled trial, patients are applying TAT4 Gel to their nasolabial folds for three months.
“Our faces lose volume as we age, which deepens nasolabial folds,” said Jody Levine, MD, FAAD, FAAP, a New York dermatologist recognized by New Beauty as one of the nation’s Top Beauty Doctors. “TAT4 was designed to enhance tissue volume by increasing subcutaneous fat.”
“Today, many patients and dermatologists rely on injectable dermal fillers to rejuvenate the skin,” said Michael Singer, MD, PhD, Topokine’s Chief Scientific Officer. “TAT4 is based on a simple concept—that instead of injecting foreign substances into the skin, a topical product can signal the patient’s own cells to reestablish a more youthful contour.”
About Topokine
Topokine is a clinical-stage biotechnology company developing topical prescription medications that act pharmacologically on adipocytes to contour the face and body. The company’s lead program, XAF5 Ointment, is in late-stage clinical development for reduction of undereye bags (steatoblepharon). Topokine’s pipeline also includes TAT4 Gel, which increases subcutaneous fat and is in Phase 2 development as a “topical filler” for reduction of laugh lines (nasolabial folds). The company’s assets are protected by over 75 issued and pending patents worldwide. For more information, visit www.topokine.com.
Contact: Matt Burke [email protected]
